Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Jefferies raised its price target on AxoGen, Inc. (NASDAQ:AXGN) to $25.00 from $24.00 on Tuesday, while maintaining a Buy rating on the stock. According to InvestingPro data, analyst targets for AxoGen currently range from $21 to $30, with the stock showing impressive returns of 61% over the past year.
The price target increase follows AxoGen’s second-quarter sales results, which exceeded consensus estimates by approximately 8% with double-digit growth across all markets.
Gross margins rebounded quarter-over-quarter after elevated inventory write-offs in the first quarter, surpassing consensus expectations.
AxoGen has raised its fiscal year 2025 sales growth guidance to at least 17% year-over-year, up from its previous forecast of 15-17%, compared to consensus estimates of 16%.
The company’s Avance Biologics License Application (BLA) timelines remain on track, with Jefferies viewing AxoGen as "an underappreciated growth story with good margins and catalyst path at a cheap valuation."
In other recent news, Axogen Inc . reported impressive financial results for the second quarter of 2025. The company exceeded expectations with an adjusted earnings per share (EPS) of $0.12, doubling the anticipated $0.06. Additionally, Axogen’s revenue reached $56.7 million, surpassing the forecasted $52.66 million. These results highlight the company’s strong performance during this period. The earnings and revenue figures have been a focal point for investors and analysts alike. While the company’s stock price movement was noted, it is not the primary focus here. The positive earnings report has been a significant development for Axogen Inc. and has captured the attention of the investment community.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.